Celcuity Inc. (NASDAQ:CELC) Given Consensus Rating of “Buy” by Analysts

Shares of Celcuity Inc. (NASDAQ:CELC) have earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $29.17.

CELC has been the topic of a number of recent analyst reports. Stifel Nicolaus raised their price target on shares of Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Needham & Company LLC restated a “buy” rating and set a $23.00 price target on shares of Celcuity in a report on Friday, November 15th. Lifesci Capital began coverage on Celcuity in a research report on Monday, August 26th. They set an “outperform” rating and a $27.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research report on Friday, November 15th.

Celcuity Stock Down 0.4 %

Shares of Celcuity stock opened at $12.80 on Monday. The company’s 50 day moving average price is $14.70 and its 200-day moving average price is $15.72. Celcuity has a 52-week low of $11.51 and a 52-week high of $22.19. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The stock has a market capitalization of $475.26 million, a price-to-earnings ratio of -4.90 and a beta of 0.76.

Hedge Funds Weigh In On Celcuity

Hedge funds have recently bought and sold shares of the company. nVerses Capital LLC purchased a new position in shares of Celcuity during the third quarter valued at approximately $33,000. Prospera Private Wealth LLC bought a new stake in shares of Celcuity in the third quarter worth $35,000. Values First Advisors Inc. purchased a new stake in Celcuity during the third quarter valued at $86,000. Quest Partners LLC lifted its position in Celcuity by 31.3% during the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after purchasing an additional 1,379 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Celcuity in the third quarter worth about $119,000. Institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.